Cargando…
Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
BACKGROUND: Trastuzumab emtansine (T-DM1) is an anti-HER2 antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer. One of the most severe adverse events reported with T-DM1 is hepatotoxicity. The objective of our meta-analysis is to investigate the risk of hepatic adverse...
Autores principales: | Cobert, Amani M., Helms, Catherine, Larck, Chris, Moore, Donald C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175051/ https://www.ncbi.nlm.nih.gov/pubmed/32341779 http://dx.doi.org/10.1177/2042098620915058 |
Ejemplares similares
-
Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
por: Yan, Hongjing, et al.
Publicado: (2017) -
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019) -
Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023) -
Association between serum lipids and breast cancer risk in
premenopausal women: systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2021) -
Smokeless tobacco use and circulatory disease risk: a systematic review and meta-analysis
por: Rostron, Brian L, et al.
Publicado: (2018)